SCHEMBL3460052

SCHEMBL3460052

Nc1ncc(-c2cccc(C(=O)NCc3ccccc3)c2)nc1C(=O)NCCNS(=O)(=O)c1cccc2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ ATR Q13535 9/20 0.48
▸ LDHA P00338 1/20 0.44
▸ LDHB P07195 1/20 0.44
▸ KDM4B O94953 1/20 0.44
▸ ITGB3 P05106 1/20 0.44
▸ ITGAV P06756 1/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ PIK3CD O00329 2/20 0.42
▸ PIK3CA P42336 2/20 0.42
▸ PIK3CG P48736 2/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TYRO3 Q06418 1/20 0.42
▸ PRKDC P78527 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3461813 0.95 SMN1; SMN2 (0.47) SMN1; SMN2ATRLDHALDHBKDM4B
SCHEMBL3460684 0.87 ATR (0.50) ATRLDHALDHBPIK3CDPIK3CA
SCHEMBL3461935 0.83 ATR (0.49) ATRLDHALDHBPIK3CDPIK3CA
SCHEMBL3461970 0.82 ATR (0.56) ATRLDHALDHBPRKDC
SCHEMBL3461865 0.81 ATR (0.52) SMN1; SMN2ATRLDHALDHBPRKDC
SCHEMBL3460800 0.81 ATR (0.57) ATRLDHALDHBPRKDC
SCHEMBL3461305 0.81 ATR (0.58) ATRLDHALDHBPRKDC
SCHEMBL3461585 0.79 ATR (0.56) ATRLDHALDHBPRKDC
SCHEMBL3461683 0.79 ATR (0.54) ATRLDHALDHBALDH1A1PRKDC
SCHEMBL3460196 0.79 ATR (0.54) SMN1; SMN2ATRLDHALDHBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 — — EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 — — US disclosed
EP-1501514-A4 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-08-26 — — EP disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 — — EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 SMN1; SMN2 4557/4885ATR 556/4885LDHA 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback